In a report released today, Michael Matson from Needham maintained a Hold rating on Masimo (MASI). The company’s shares closed last Monday at $230.73.
According to TipRanks.com, Matson is a 5-star analyst with an average return of 7.3% and a 56.0% success rate. Matson covers the Healthcare sector, focusing on stocks such as Axonics Modulation Technologies, Cardiovascular Systems, and Zimmer Biomet Holdings.
Currently, the analyst consensus on Masimo is a Moderate Buy with an average price target of $269.20, a 18.6% upside from current levels. In a report issued on October 27, BTIG also maintained a Hold rating on the stock.
See today’s analyst top recommended stocks >>
Masimo’s market cap is currently $12.32B and has a P/E ratio of 58.00. The company has a Price to Book ratio of 9.65.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Masimo Corp. is a medical technology company, which develops, manufactures and markets non invasive patient monitoring technologies, medical devices and sensors. Its products include continuous monitors, patient-worn monitors, hospital automation connectivity, capnography & gas, data download & analytics and sensors & accessories. The company was founded by Joe E. Kiani in May 1989 and is headquartered in Irvine, CA.
